Acupuncture for diabetic peripheral neuropathy: study protocol for a randomized, placebo-controlled trial

Haiping Deng
Shanghai University of Traditional Chinese Medicine
https://orcid.org/0000-0001-7124-5716

Yu Shu
Shanghai University of Traditional Chinese Medicine

Peiran Lv
Shanghai University of Traditional Chinese Medicine

Ling Zhao
Shanghai University of Traditional Chinese Medicine

Ke Cheng
Shanghai University of Traditional Chinese medicine, Shanghai Research Center for Acupuncture and meridian

Tingting Zhang
Shanghai University of Traditional Chinese Medicine

Yi Song
Long-Hua Hospital affiliated to Shanghai University of Traditional Chinese Medicine

Hua Yang
Long-Hua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

Hong Tang
Long-Hua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

Jian Pei
Long-Hua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

Xueyong Shen
sxy1@shutcm.edu.cn
https://orcid.org/0000-0003-4177-8970

Study protocol

**Keywords:** Acupuncture, Diabetic peripheral neuropathy, Randomized controlled trial, Study protocol

**DOI:** https://doi.org/10.21203/rs.3.rs-18355/v2

**License:** This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

**Background:** Diabetic peripheral neuropathy (DPN) is the most common chronic complication of diabetes mellitus that has a considerable impact on quality of life, but there are few effective therapeutic strategies. The aim of this trial is to determine the efficacy and safety of manual acupuncture (MA) versus sham acupuncture (SA) for DPN.

**Methods/Design:** This is a study protocol for a randomized, placebo-controlled clinical trial. A total of 118 patients with DPN will be recruited and randomly assigned in a 1:1 ratio to either MA group or SA group. All patients will receive 24 sessions over 12 weeks. Participants will complete the trial by visiting the research center at month 6 for a follow-up assessment. The primary outcome is peroneal motor nerve conduction velocity (peroneal MNCV) at week 12 compared with baseline. Secondary outcomes include peroneal motor nerve action potential amplitude (peroneal MNAP) and latent period (peroneal MNLP), sural sensory nerve conduction velocity (sural SNCV), action potential amplitude (sural SNAP) and latent period (sural SNLP), fasting plasma glucose (FPG), 2-hour postprandial blood glucose (2hPG), glycated hemoglobin (HbAlc) at week 12 compared with baseline, Michigan Neuropathy Screening Instrument (MNSI) score and Diabetes Specific Quality of Life scale (DSQL) at week 12 and month 6 compared with baseline. Safety will be assessed during the whole trial. Masking effectiveness will be assessed by patients.

**Discussion:** This trial may provide high-quality evidence for evaluating the efficacy and safety of MA treatment for DPN compared with SA treatment. Results of this study will be published in peer-reviewed journals.

**Trial registration:** Chinese Clinical Trials Registry, ID: ChiCTR1800020444. First registered on 29 December 2018 - Retrospectively registered, http://www.chictr.org.cn/showproj.aspx?Proj=31063

**Background**

DPN is the most common cause of neuropathy worldwide, and its prevalence increases with the duration of diabetes [1]. Approximately 50% of patients with diabetes will develop peripheral neuropathy [1,2,3]. DPN is symmetric and predominantly sensory, starting distally and gradually spreading proximally in a glove-and-stock ing distribution [1]. DPN is associated with the development of foot problems such as foot ulcers, and is one of the leading causes of amputations. The high-frequency underreport and undertreatment of DPN can lead to an increased risk for morbidity and mortality and decreased quality of life [1,2]. Once symptoms appear, there are few effective therapeutic strategies [4]. Whilst neuropathic pain and paresthesia can be palliated by anti-convulsant drugs, tricyclic antidepressant drugs or serotonin-noradrenalin re-uptake inhibitors [5], pharmacological management of decreased sensation is generally ineffective. Therefore, more and more patients turn to seek non-pharmacological treatments. Multiple complementary and alternative medicine therapies such as acupuncture and yoga have shown efficacy in the treatment of painful peripheral neuropathy [6]. A pilot RCT has demonstrated practicality
and feasibility of acupuncture as an additional well-tolerated treatment without appreciable side effects for people with DPN [7]. Acupuncture may effectively ameliorate selected DPN symptoms—such as aching pain, burning pain, prickling sensation, numbness, allodynia in American Indian patients [8]. Reviews concerning acupuncture for peripheral neuropathy (PN) have found that, despite the majority of studies reporting positive results, a reliable statement of effectiveness is not possible due to methodological limitations [9-12]. A recent systematic review on acupuncture for DPN indicates the treatment appears to improve symptoms [13]. However, owing to problems such as unsuitable control group and blinding, strong non-specific effects cannot be ruled out. Also, inconsistency of outcome measures and lack of use of global neuropathy-specific patient-reported outcome measures have confounded results. Overall, the quality of acupuncture intervention delivered in individual studies was low. Appropriately powered RCTs with suitable control groups, validated and proper outcome measures for DPN patients, and more accurate reporting of acupuncture interventions, including point selection rationales, point locations and practitioner qualifications, are needed [13]. Therefore, we have designed a randomized, sham-controlled, participant-blinded and assessor-blinded study with a 6-month observation period to explore its effectiveness and safety.

**Methods**

**Study design**

This randomized, participant-blind, sham controlled trial will be conducted at Long-Hua Hospital affiliated to Shanghai University of Traditional Chinese Medicine in China. The protocol for this trial is reported based on the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) 2013 Checklist: defining standard protocol items for clinical trials (Additional file 1). The study has been approved by the Ethics Committee of Long-Hua Hospital (Ethical approval number: 2016LCSY028), and registered on the Chinese Clinical Trial Registry (Chictr) platform since 29 December 2018 (Registration number: ChiCTR1800020444). A flow diagram of the trial is shown in Fig. 1.

**Patient recruitment**

Patients meet ADA 2012 diagnostic criteria for DPN will be recruited from the endocrinology departments of Long-Hua Hospital affiliated to Shanghai University of Traditional Chinese Medicine in Shanghai, China. Recruitment posters will be posted in the hospital and uploaded to social media (WeChat) from October 2016 to December 2021. All patients will be required to provide written informed consent (Additional file 2) before randomization.

**Inclusion criteria**

Participants who meet all the following requirements will be allowed for enrollment:

1. Aged 18–75 years (either sex);
2. Patients who meet diagnosis of DPN defined by the American Diabetes Association (ADA) in 2005 [14].

3. DPN is defined as the presence of symptoms and/or signs of peripheral nerve dysfunction in people with diabetes, after the exclusion of other causes.

4. NP is defined as altered sensitivity to pressure and (1) altered sensitivity to pain or (2) altered sensitivity to vibration or (3) achilles reflex [15].

5. Symmetric and predominantly sensory, starting from the lower limbs distally and gradually spreading proximally in a glove-and-stocking distribution;

6. Ability to understand study procedures and willingness to comply with them for the entire period of study;

7. Written informed consent

**Exclusion criteria**

Participants meeting any of the following criteria will be excluded:

1. PN caused by conditions other than diabetes (e.g., alcohol abuse, chemotherapy, hereditary causes, chronic inflammatory or idiopathic PN);

2. Psychiatric illnesses other than mild depression;

3. Severe or unstable cardiovascular, liver, kidney, respiratory or hematological disorders;

4. Received acupuncture treatment in the last 3 months;

5. Pregnant or lactating women;

6. Research unit personnel directly related to the study and their immediate family members;

7. Incapable of giving informed consent or following the study instructions due to language disturbances, serious cognitive deficits, or lack of time;

8. Currently participating in other clinical trials.

**Randomization and allocation concealment**

All eligible patients will be randomly assigned to MA group or SA group in a 1:1 ratio. The blocked randomization sequence will be computer-generated (EXCEL) by an independent statistician, who will not be involved in implementation and statistical analysis of the trial. The allocation will be placed inside sequentially numbered sealed opaque envelopes which will be opened only after enrollment. The treatment allocation will be revealed to acupuncturists out of patients’ sight to ensure blinding. To reduce the risk of observer bias, the acupuncture practitioners will be discouraged from discussing treatments or previous results with patients. The random allocation sequence and sealed opaque envelopes will be kept separately by two specific researchers. The clinical research coordinator will be responsible for enrolling patients, obtaining informed consent and requesting randomization.

**Masking**
Due to the nature of acupuncture, masking of acupuncturists is quite difficult to achieve. Patients, outcome assessors, and statisticians who perform the statistical analyses will be blinded to group assignment. The treatments subjects received will be not revealed until the statistical analysis is completed.

**Interventions**

Treatment will be performed by licensed acupuncturists who have at least five years of experience in acupuncture. All the acupuncturists will be trained how to locate acupoints, puncture, and manipulate needles before trials. A placebo device [16,17] will be applied in both groups for better implementation of blindness. Both MA and SA treatments will consist of 24 sessions over 12 weeks (40 min per session, two sessions per week). Acupuncture will be discontinued if patients suffer from any serious adverse events (AEs).

**Manual acupuncture**

Patients allocated to MA group will receive treatment with needles being inserted at the prespecified acupuncture points through the placebo device. Obligatory and additional acupoints adopted in this protocol are developed from clinical experiences of acupuncture experts. The obligatory acupoints include Zhongwan (CV12), bilateral Weiwanxiashu (EX-B3), bilateral Ganshu (BL18), bilateral Pishu (BL20), bilateral Shenshu (BL23), bilateral Zusanli (ST36), bilateral Yanglingquan (GB34), bilateral Sanyinjiao (SP6), bilateral Taixi (KI3), and Bafeng (EX-LE10). Additional acupoints Baxie (EX-UE9) will be added when patients’ symptoms appear not only in the lower limbs but also in the upper limbs. All acupoints are localized according to the WHO Standard Acupuncture Locations and exhibited in Table 1 and Fig. 2. After skin disinfection, disposable, stainless steel acupuncture needles (0.25 × 25mm or 0.25 × 40mm, provided by Wuxi Jiajian Medical Instrument Co. Ltd., China) will be inserted into the skin of acupoint (approximately 10-20mm depth), then manipulations of twirling, lifting and thrusting will be performed on all needles for at least 10s to reach De qi (a compositional sensation including soreness, numbness, distention and heaviness), which is believed to be an essential component for acupuncture efficacy. Firstly, CV12, ST36, GB34, SP6, KI3, EX-LE10 and EX-UE9 will be punctured when patients lie supine. Then, EX-B3, BL18, BL20 and BL23 will be punctured when patients lie prone. Needles will be retained in these acupoints for 20min.

**Sham acupuncture**

Patients in SA group will receive sham acupuncture. The procedure and duration of treatment in the SA group will be identical in the MA group except the needles (0.25 × 25mm, blunt tip, provided by Wuxi Jiajian Medical Instrument Co. Ltd., China) are blunt tip and there will be no skin penetration and needle manipulation for De qi.

Although it is difficult to set an eligible placebo control, using blunt tipped needles which do not penetrate patient's skin is the most common approach for administering sham treatments among acupuncture
trials, according to a literature review [18,19]. Moreover, this study will exclude those who have received acupuncture treatment in the last 3 months and can distinguish SA from MA. The same control with no skin penetration at acupoints was adopted and succeeded in masking patients with DPN [7, 16, 17]. Furthermore, all patients will be asked to guess which treatment they have received to test the patient-blinding effects at week 12.

Table 1 Locations and manipulations of acupoints

| Acupoint       | Location                                                                 | Manipulation                              |
|----------------|---------------------------------------------------------------------------|-------------------------------------------|
| Obligatory acupoints | Zhongwan (CV12) | On the anterior midline, 4 cun\(^a\) above the umbilicus | Puncture perpendicularly to a depth of 1.0-1.2 cun |
|                | Weiwanxiashu (EX-B3) | at the same level as the inferior border of the spinous process of the 8th thoracic vertebra (T8), 1.5 cun lateral to the posterior median line | Puncture obliquely and medially to a depth of 0.5-0.8 cun |
|                | Ganshu (BL18) | at the same level as the inferior border of the spinous process of the 9th thoracic vertebra (T9), 1.5 cun lateral to the posterior median line | Puncture obliquely and medially to a depth of 0.5-0.8 cun |
|                | Pishu (BL20) | at the same level as the inferior border of the spinous process of the 11th thoracic vertebra (T11), 1.5 cun lateral to the posterior median line | Puncture obliquely and medially to a depth of 0.5-0.8 cun |
|                | Shenshu (BL23) | at the same level as the inferior border of the spinous process of the 2nd lumbar vertebra (L2), 1.5 cun lateral to the posterior median line | Puncture perpendicularly to a depth of 0.8-1.2 cun |
|                | Zusanli (ST36) | 3 cun directly below Dubi (ST35), and one finger-breadth lateral to the anterior border of the tibia | Puncture perpendicularly to a depth of 1.0-1.2 cun |
|                | Yanglingquan (GB34) | in the depression anterior and distal to the head of the fibula | Puncture perpendicularly to a depth of 1.0-1.2 cun |
|                | Sanyinjiao (SP6) | 3 cun superior to the prominence of the medial malleolus, posterior to the medial border of the tibia, | Puncture perpendicularly to a depth of 1.0-1.2 cun |
|                | Taixi (KI3) | in the depression between the prominence of the medial malleolus and the calcaneal tendon | Puncture perpendicularly to a depth of 0.5-0.8 cun |
|                | Bafeng (EX-LE10) | on the dorsum of the foot, between the first and fifth toes at the junction of the red and white skin posterior to the margin of the web; 4 points on each foot, 8 in total | Puncture obliquely and medially to a depth of 0.5-0.8 cun |
| additional acupoints for upper limbs syndrome | Baxie (EX-UE9) | at the dorsum of the hand, between the first and fifth fingers, proximal to the web margins between the five fingers at the junction of the red and white skin, 4 points on each hand, 8 in total | Puncture obliquely upward to a depth of 0.5-0.8 cun |

\(^{a}\)1 cun \(\approx 20\text{mm}\) is defined as the width of the interphalangeal joint of patient’s thumb

**Concurrent Treatments**

Participants will receive routine health care as provided to all other patients with DPN. These treatments include glucose control, antihypertensive therapies, dyslipidemia control, analgesic and neurotrophic treatments, if necessary. All information regarding the use of medications (including date of administration, types and dosage) will be recorded. This will contribute to improving adherence.
Follow-up

After 12-week treatments, all participants will enter an additional 3 months follow-up period. During this time, they will receive routine health care as provided to all other patients with DPN. However, acupuncture treatment will not be permitted during follow-up.

Outcomes

Primary endpoint

The primary endpoint is comparing two groups’ difference before and after treatment in terms of peroneal motor nerve conduction velocity (peroneal MNCV).

Key secondary endpoints

Secondary endpoints are comparing two groups’ difference before and after treatment in terms of peroneal motor nerve action potential amplitude (peroneal MNAP) and latent period (peroneal MNLP), sural sensory nerve conduction velocity (sural SNCV), action potential amplitude (sural SNAP) and latent period (sural SNLP).

Additional secondary endpoints include: Glycated hemoglobin (HbA1c), fasting plasma glucose (FPG), 2-hour postprandial blood glucose (2hPG), Body mass index (BMI) and blood pressure (BP) at week 12 will be compared with baseline, Michigan Neuropathy Screening Instrument (MNSI) score at week 12 and month 6 will be compared with baseline.

Quality of life (QoL)

Disease-specific QoL will be assessed at baseline and at week 12, month 6 after randomization using Diabetes Specific Quality of Life scale (DSQL). The scale consists of four domains: interference (12 items), psychology (8 items), social relations (4 items) and treatment (3 items). Each item is measured with a 5-point Likert scale ranging from “not at all” to “extremely”. Higher scores indicate worse QoL.

Patients’ global assessment of DPN
Patients’ global assessment of DPN will be evaluated on a 5-point Likert scale at week 12. Patients will be asked to respond to the following question: “Considering all the ways your DPN affects you, how are you doing today?” 1=very poor; 2=poor; 3=fair; 4=good; or 5=very good.

**Blinding assessment**

To test the patient-blinding effects, all patients will be asked to guess their group assignment allocation within 2min after the last treatment session at week 12 as following: “Which group do you think you are in?” A. traditional acupuncture; B. modified acupuncture; or C. not sure.

**Credibility and expectancy**

Credibility and expectancy of patients will be assessed by a Likert-scale Credibility/Expectancy Questionnaire (see Table 2) before the first treatment.

| Statement                                      | Strongly disagree | Disagree | Neutral | Agree | Strongly agree |
|------------------------------------------------|-------------------|----------|---------|-------|----------------|
| a. My illness will get much better.           | £1                | £2       | £3      | £4    | £5             |
| b. I will face my disease better.             | £1                | £2       | £3      | £4    | £5             |
| c. Symptoms of my disease will disappear.     | £1                | £2       | £3      | £4    | £5             |
| d. I will be more vigorous than before.       | £1                | £2       | £3      | £4    | £5             |

**Adverse events**

AEs data will document the occurrence, duration, and severity of adverse reactions (symptoms and signs), and how the event was resolved (or not) during the treatment. Based on their potential association with the acupuncture needling procedure, AEs will be categorized by acupuncturists and related specialists as treatment-related or not within 24h after occurrence. Common treatment-related AEs include local subcutaneous hematoma, itching at the sites of needle insertion, continuous post-needling pain, dizziness, and so on. All participants will receive routine blood test, liver function (alanine transaminase and aspartate transaminase), and kidney function tests (serum creatinine and blood urea nitrogen). These tests will be performed twice, after randomization and at the end of 12-week treatment period. Serious adverse events will be reported to Medical Ethics Committee and the participant will be
treated with relevant conventional therapy or hospitalization if necessary (the participant’s allocated intervention will be revealed).

**Assessment of safety**

Patients will be asked to assess safety of treatments after 12 weeks’ treatments, using a four-grade scale: safe, relatively safe, unsafe, and very unsafe.

**Sensation during the treatment**

Patients will be asked about their sensation during each treatment period as following: “What sensation do you feel during the treatment? A. soreness; B. distention; C. pain; D. no feeling; E. else, please specify___.”

**Usage of medication**

Medication Usage Log: Participants will be given a printed log to record their daily intake of prescribed medications. We will measure outcomes at week 12.

The schedule of enrollment, interventions, and assessments are presented in Fig. 3.

**Data collection, management and monitoring**

All researchers including acupuncturists, outcome assessors, and statisticians will receive training regarding data management. Case Report Forms (CRFs) will be completed and double entered into the Electronic Data Capture (EDC) system by two independent investigators to ensure accuracy of data.

All research documents, including both paper files and electronic documents, will be preserved for at least five years after publication. If reviewers or readers have any questions regarding our published data, they can contact corresponding author for access to original data or visit ResMan (http://www.medresman.org/uc/project/projectadd.aspx). Private information of patients including name, telephone number and ID number will be anonymous to ensure participant confidentiality.

Safety of this study will be monitored by a team consists of independent clinical experts and statisticians with access to unblinded data from Data and Safety Monitoring Board (DSMB) of the clinical evaluation center of Long-Hua Hospital, affiliated to Shanghai university of TCM. DSMB is independent from the sponsor, the competing interests and the investigational site and will review performance and safety of the trial every six months.

The criteria for unblinding and discontinuing allocated interventions for any trial participant experiencing serious acupuncture-related AEs have been described previously. DSMB will reveal a participant’s allocated intervention, and make the final decision on whether to terminate the trial.

**Statistical methods**
Sample size

Based on results of a previous study [20], a sample size of 47 participants per group was estimated to provide 80% power to detect a between-group difference of 2.4 m/s of conduction velocity improvement of common peroneal nerve, with a pooled standard deviation of 4.15 m/s and an alpha level of 0.05. The assumption of a conservative 20% drop-out rate in any group increases the sample size to 59 participants per group or 118 participants in total.

Statistical analysis

Statistical analysis will be performed by an independent statistician who is not aware of group allocation. SPSS 21.0 (IBM SPSS Statistics, New York, USA) will be used for data analysis. Level of significance will be established at $\alpha < 0.05$ with a two-sided test. Continuous data will be represented by mean ± standard deviation or median (range), and categorical data will be represented by percentage. All efficacy analyses will be performed using the intent-to-treat (ITT) approach. For the ITT analysis, population will consist of all patients who have been randomized. Missing data will be imputed using the last observation carried forward (LOCF) method. Continuous variables will be compared using Student's t-test or Wilcoxon rank-sum test as appropriate. Categorical variables will be compared using Fisher's exact test or Wilcoxon rank-sum test as appropriate. Analysis of covariance (ANCOVA) or logistic regression will be used for analysis and adjustment of baseline characteristics that differ significantly between two groups.

Ethics and dissemination

The study protocol which follows principles of the Declaration of Helsinki has been approved by the Medical Ethics Committee of Long-Hua Hospital affiliated to Shanghai University of Traditional Chinese Medicine since 7 July 2016 (Approval Number: 2016LCSY028) and registered on the Chinese Clinical Trial Registry, ChiCTR1800020444. Results will be disseminated through peer-reviewed publications, a master's thesis, or conference presentations. Data will be anonymized prior to publication to prevent identification of individual participants.

Discussion

Diabetes mellitus (DM) is a common disease which is accompanied by highly significant social and economic burdens [21]. According to the International Diabetes Federation (IDF), DM affects 415 million people worldwide, with a prevalence of 8.8%, and these values are expected to rise still further to 642 million by the year 2040, with a prevalence of 10.4% [22]. DPN is one of the most frequent complications of DM and usually characterized by gradually increases in pain severity, impairments in tactile and proprioceptive sensation, vibration sense, and improper postural control [23]. DPN is commonly associated with high rates of mortality and morbidity [24]. Acupuncture has been widely used in clinical practice for the treatment of DPN in China. However, so far there has been no appropriately designed randomized controlled trial to provide clear evidence about the effectiveness of acupuncture treatment for DPN at home and abroad.
In this study, the inclusion criterion of age, from 18 to 75 years, was chosen to cover age range as wide as possible. We cooperated with the endocrinology department of Long-Hua Hospital affiliated to Shanghai University of Traditional Chinese Medicine to ensure the required number of subjects recruited. During the study period, patients will receive routine health care as provided to all other patients with DPN. Usually we encourage them not to change their medications, but adjusting medications will be permitted if necessary. We believe this strategy can reflect real-world practice and satisfy ethical obligations better.

A standardized treatment protocol will be utilized to assure reproducibility of the study. In this trial, the treatment protocol was based on traditional acupuncture theory, previous studies [17] and the consensus of endocrinologists and acupuncturists from Long-Hua Hospital affiliated to Shanghai University of Traditional Chinese Medicine. The amount of acupuncture is intensive, which is similar to clinical practice in China. Needles will be stimulated manually for at least 10s at each acupoint and retained in place for 20 min. There will be 2 treatment sessions per week within the course of 12-week treatment, giving a total of 24 sessions.

A suitable control group is critical for a well-designed clinical trial. On the basis of literature review, using a blunt tipped needle which does not penetrate patient’s skin is the most commonly used approach for administering sham treatments among acupuncture trials [18,19]. Patients who have received acupuncture treatment in the last 3 months and can distinguish SA from MA will be excluded. The same control group design, no skin penetration at acupoints, was adopted and succeeded in masking patients with DPN [7, 16, 17]. Furthermore, all patients will be asked to guess which treatment they have received to test patient-blinding effects at week 12.

The change of nerve conduction velocity is chosen as the primary outcome because it is the highest sensitive and objective method to detect neuropathy [25]. Multiple systematic reviews [11,13] recommended nerve conduction velocity as a main outcome, and it had been widely used as an outcome measure in DPN studies [26, 27]. At the same time, assessment of the severity of DPN mainly depends on patient-reported outcomes. The MNSI is the most DPN-specific patient-reported measure [13]. In this trial, we use the DSQL to evaluate quality of life in patients with DPN before and after acupuncture treatment. The DSQL captures the impact of detailed aspects of modern diabetes management (e.g., carbohydrate counting and flexible insulin dose adjustment) that is extensively used in evaluating quality of life in DM. The DSQL offers a valuable tool for assessing the impact of treatment approaches on QoL in adults with DM [28].

The limitation of our trial is acupuncturists are not blinded for the nature of intervention. We hope results of this trial will provide more reliable evidence and clarify the value of acupuncture as a treatment for DPN.

To summarize, this trial meets the methodological demand of adequate randomization and allocation concealment, blinding of patients, outcome assessors, and statisticians. Findings of this study will provide high-quality evidences for evaluating the efficacy and safety of acupuncture treatment for DPN.
Trial status

This trial is currently recruiting patients. This is version 2.0 of the protocol, dated June 6th, 2016. Recruitment began on 10 October 2016 and the anticipated end date is 31 December 2021.

Declarations

Acknowledgements

Funding

This study was supported by the Three-Year development plan project for Traditional Chinese Medicine of Shanghai Municipal Health Commission (grant numbers ZY (2018-2020)-CCCX-1006. The funding play no role in study design, collection, management, analysis, interpretation of data, writing of the report, or the decision to submit the report for publication.

Availability of data and materials

All de-identified data collected during the trial will be available for anyone who wishes to access six months after publication in accordance with FAIR principles.

Authors’ contributions

HPD, XYS, HY, HT, and JP participated in the conception and design of this trial. HPD, LZ , YS and JP were responsible for planning the draft and revising the manuscript. JP and XYS are monitors of this study. KC is responsible for randomization and allocation concealment. HY and HT are responsible for the recruitment of patients and obtain informed consent. HPD, TTZ and YS are responsible for the treatment of patients. YS and PRL are responsible for collecting the data. All authors have read the manuscript and approved the publication of this protocol.

Ethics approval and consent to participate

The study is approved by the Medical Ethics Committee of Long-Hua Hospital affiliated to Shanghai University of Traditional Chinese Medicine, (Approval No. 2016LCSY028) and registered with Chinese Clinical Trial Registry, ChiCTR1800020444. Written informed consent will be obtained from all patients prior to their enrollment in the study.

Author details

1 School of Acupuncture-Moxibustion and Tuina, Shanghai University of Traditional Chinese Medicine, Pudong District, Shanghai, China

2 Shanghai Research Center of Acupuncture and Meridian, Pudong District, Shanghai, China
Competing interests

The authors declare that they have no competing interests.

Abbreviations

ADA: the American Diabetes Association; AEs: Adverse events; BMI: Body mass index; BP: blood pressure; CRF: Case report form; DM: Diabetes mellitus; DPN: Diabetic peripheral neuropathy; DSMB: Data and Safety Monitoring Board; DSQL: Diabetes Specific Quality of Life scale; FPG: fasting plasma glucose; HbA1c: glycated hemoglobin; 2hPG: 2-hour postprandial blood glucose; IDF: International Diabetes Federation; ITT: Intent-to-treat; MA: Manual acupuncture; MNAP: Motor nerve action potential amplitude; MNCV: Motor nerve conduction velocity; MNLP: motor nerve action potential latent period; MNSI: Michigan Neuropathy Screening Instrument; PN: Peripheral neuropathy; QoL: Quality of life; SA: sham acupuncture; SNAP: sensory nerve action potential amplitude; SNCV: sensory nerve conduction velocity; SNLP: sensory nerve action potential latent period.

References

1. Iqbal Z, Azmi S, Yadav R, Ferdousi M, Kumar M, Cuthbertson DJ, Lim J, Malik RA, Alam U. Diabetic Peripheral Neuropathy: Epidemiology, Diagnosis, and Pharmacotherapy. Clinical Therapeutics. 2018;40:828-49.
2. Denise SH. Diabetic Peripheral Neuropathy: Evaluation and Management, The Journal for Nurse Practitioners. 2017; 13:199-204.
3. Gordon S, Pallai S, Dinesh S, Jing W, Iain DW, Irene T, Praveen A, Solomon T. A new look at painful diabetic neuropathy. Diabetes Research and Clinical Practice. 2018; 144:177-91.
4. Won JC, Kim SS, Ko KS, Cha BY. Current Status of Diabetic Peripheral Neuropathy in Korea: Report of a Hospital-Based Study of Type 2 Diabetic Patients in Korea by the Diabetic Neuropathy Study Group of the Korean Diabetes Association. Diabetes Metab J. 2014; 38:2531.
5. Ziegler D, Fonseca V. From guideline to patient: a review of recent recommendations for pharmacotherapy of painful diabetic neuropathy. J Diabetes Complications. 2015; 29: 146–56.
6. Baute V, Zelnik D, Curtis J, Sadeghifar F. Complementary and Alternative Medicine for Painful Peripheral Neuropathy.[J].Current Treatment Options In Neurology.2019; 21:44.
7. Garrow AP, Xing M, Vere J, Verrall B, Wang L, Jude E. Role of acupuncture in the management of diabetic painful neuropathy (DPN): a pilot RCT. Acupuncture in medicine. 2014; 32:242–9.
8. Anne B, Deborah W, Matthew A, Priscilla S, Daniel C. Acupuncture Treatment of Diabetic Peripheral Neuropathy in an American Indian Community[J]. Journal of acupuncture and meridian studies.2017;10:90-95.
9. Franco LC, Souza LAF, Da Costa Pessoa AP, Pereira LV. Nonpharmacologic therapies in diabetic neuropathic pain: a review. Acta Paulista de Enfermagem. 2011;24(2):284–8.

10. Chen B, Zhao X, Guo Y, Chen ZL, Bai Y, Wang ZX, Wang YJ. Assessing the Quality of Reports about Randomized Controlled Trials of Acupuncture Treatment on Diabetic Peripheral Neuropathy. PLoS Clinical Trials. 2012; 7(7):1.

11. Franconi G, Manni L, Schröder S, Marcetti P, Robinson N. A Systematic Review of Experimental and Clinical Acupuncture in Chemotherapy-Induced Peripheral Neuropathy. Evidence-Based Complementary and Alternative Medicine. 2013; doi: 10.1155/2013/ 516916.

12. Dimitrova A, Murchison C, Oken B. Acupuncture for the Treatment of Peripheral Neuropathy: A Systematic Review and Meta-Analysis. Journal of Alternative & Complementary Medicine.2017;23:164-179.

13. Nash J, Armour M, Penkala S. Acupuncture for the treatment of lower limb diabetic peripheral neuropathy: a systematic review. Acupuncture in Medicine. 2019; 37:3-15. doi:10.1136/acupmed-2018-011666

14. Boulton AJM, Vinik AI, Arezzo JC, Bril V, Feldman EL, Freeman R, Malik RA, Maser RE, Sosenko JM, Ziegler D. Diabetic neuropathies: a statement by the American diabetes association. J Diabetes Care.2005;28:956-962.

15. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2012; 35(Suppl 1): S64–S71

16. Liu B, Xu H, Ma R, Mo Q, Yan S, Liu Z. Effect of blinding with a new pragmatic placebo needle: A randomized controlled crossover study. Medicine (Baltimore). 2014;93:e200.

17. Wang Q, Deng HP, Cheng K, Huang ZQ, Yin XQ, Zhou YC, Yang YQ, Shen WD, Zhao L, Shen XY. Manual acupuncture for the infertile female with polycystic ovary syndrome (PCOS): study protocol for a randomized sham-controlled trial. J Trials.2019;20:564.

18. Wang YR, Zhao JP, Hao DF. Is sham acupuncture a real placebo: Skeptical for sham acupuncture. World Journal of Acupuncture - Moxibustion.2017;27:1-5.

19. Zhang LL, Chu Q, Wang S, Lai H, Xie BB. Is Sham Acupuncture as Effective as Traditional Chinese Acupuncture? It’s too Early to Say. Chinese Journal of Integrative Medicine. 2016; 22:483-9.

20. Wu M, Zhang M, Wang RM, Wang DY. Clinic Study on the Treatment of Diabetic Peripheral Neuropathy by Acupuncture. China Journal of Chinese Medicine, 2015; 30(6):810-812

21. Maronesi CT, Cecagno-Zanini SC, de Oliveira LZ, Bavaresco SS, Leguisamo CP. Physical exercise in patients with diabetic neuropathy: systematic review and meta-analysis of randomized clinical trials. J Fisioter Pesqui.2016;23:216-23.

22. Esther C, Francisco J. Pomares-Gómez; Ana Belén Ortega-Ávilac; Manuel Coheña-Jiménezd; Gabriel Gijon-Nogueronce. Variability in the clinical diagnosis of diabetic peripheral neuropathy. J Primary Care Diabetes.2020;14:53-60.

23. Akbari M, Jafari H, Moshashaee A, Forugh B. Do diabetic neuropathy patients benefit from balance training? J Journal of Rehabilitation Research and Development.2012; 49:333-38.
24. Yamany AA, Sayed HM. Effect of low level laser therapy on neurovascular function of diabetic peripheral neuropathy. J Journal of Advanced Research.2012;3:21-8.

25. Kaku M, Vinik A, Simpson DM. Pathways in the diagnosis and management of diabetic poly neuropathy. J Current Diabetes Reports.2015;15:609.

26. Jiang H, Shi K, Li X, Zhou W, Cao Y, Wang X. Clinical study on the wrist-ankle acupuncture treatment for 30 cases of diabetic peripheral neuritis. J Journal of Traditional Chinese Medicine.2006;26:8-12.

27. Tong Y, Guo H., Han B. Fifteen-day acupuncture treatment relieves diabetic peripheral neuropathy. J Journal of Acupuncture and Meridian Studies.2010;3:95-103

28. Cooke D, O'hara MC, Beinart N, Heller S, La Maecca R, Byrne M, Mansell P, Dinneen SF, Clark M, Bond R, Speight J. Linguistic and Psychometric Validation of the Diabetes-Specific Quality-of-Life Scale in U.K. English for Adults with Type 1 Diabetes. J Diabetes Care.2013;36:1117-1125.

Figures
Figure 1

Flow diagram
Figure 2

All acupoints are localized according to the WHO Standard Acupuncture Locations and exhibited in Table 1 and Fig. 2.
### Figure 3

The schedule of enrolment, interventions, and assessments

| TIMEPOINT      | STU D PERI O D | Enrolment | Allocation | Treatment period | Follow-up period |
|----------------|---------------|-----------|------------|------------------|------------------|
| ENROLMENT:     |               | -1 week   | 0          | 1-11 week        | 12 week          | 5 month          |
| Eligibility screen |               |           | X          |                  |                  |                  |
| Informed consent |               |           | X          |                  |                  |                  |
| Allocation     |               |           |            |                  |                  | X                |
| Credibility and expectancy |   |           |            |                  |                  | X                |
| INTERVENTIONS: |               |           |            |                  |                  |                  |
| Acupuncture group |           |           | X          | X                |                  |                  |
| Sham Acupuncture group |   |           | X          | X                |                  |                  |
| ASSESSMENTS:   |               |           |            |                  |                  |                  |
| peroneal MNCV, INAP, MNLG |   |           |            | X                |                  |                  |
| sural SNCV, SNAP, SNLP |   |           | X          |                  |                  |                  |
| MNSI |               |           | X          |                  |                  | X                |
| DSQL |               |           | X          | X                |                  |                  |
| HbA1c |            |           |            | X                |                  |                  |
| FPG |               |           |            | X                |                  |                  |
| 2hPGE |            |           |            | X                |                  |                  |
| BMI |               |           | X          |                  |                  | X                |
| EP |               |           | X          |                  |                  | X                |
| Routine blood test |           |           | X          |                  |                  | X                |
| Liver function test |           |           | X          |                  |                  | X                |
| Kidney function test |           |           | X          |                  |                  | X                |
| Usage of medication |           |           | X          |                  |                  | X                |
| Sensation during the treatment |   |           | X          |                  |                  | X                |
| Adverse events |               |           |            |                  | X                | X                |
| Blinding assessment |           |           |            |                  |                  | X                |
| Patients’ global assessment |   |           |            |                  |                  | X                |
| Assessment of safety |           |           |            |                  |                  | X                |